Skip to main content

Advertisement

SpringerLink
Log in

Primary central nervous system lymphoma

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

There is no class I evidence for any therapeutic option in primary central nervous system lymphoma (PCNSL). When possible, patients should be included in clinical trials. The role of surgery is restricted to stereotactic biopsy in order to gain material for histopathologic diagnosis. Radiotherapy alone is associated with a median survival of no more than 1.5 years; cure is exceptional. However, in patients aged younger than 60 years, cure is the therapeutic aim. Polychemotherapy based on high-dose methotrexate with deferred radiation results in long-term survival in most of these patients and possibly cure in a substantial fraction of these patients. With regard to chemotherapy in PCNSL, the following must be considered: 1) the most efficient drug in PCNSL is methotrexate at a dosage of at least 1.5 g/m2 per single dose; 2) methotrexate alone will lead to complete remission in only some patients, whereas the combination of methotrexate with other drugs is more efficient; and 3) the value of additional intraventricular chemotherapy and the necessity of “consolidation” radiotherapy after response to chemotherapy are not yet defined. For patients aged older than 60 years, no curative regimen with acceptable toxicity has yet been established. The combination of radiotherapy with methotrexate-based chemotherapy leads to severe long-term neurotoxic sequelae, ie, cognitive dysfunction, in most older patients and in some patients aged younger than 60 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Schlegel U, Schmidt-Wolf IGH, Deckert M: Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000, 181: 1–12.

    Article  PubMed  CAS  Google Scholar 

  2. Central Brain Tumor Registry of the United States, Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Chicago, IL: Central Brain Tumor Registry of the United States; 2005.

  3. Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 2001, 56: 257–260.

    PubMed  CAS  Google Scholar 

  4. Ferreri AJ, Blay JY, Reni M, et al.: Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002, 13: 531–538.

    Article  PubMed  CAS  Google Scholar 

  5. Abrey LE, Batchelor TT, Ferreri AJM et al.: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005, 23: 5034–5043. International consensus on criteria for baseline evaluation and response analysis in clinical trials on PCNSL.

    Article  PubMed  Google Scholar 

  6. Küker W, Nägele T, Korfel A, et al.: Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005, 72: 169–177.

    Article  PubMed  Google Scholar 

  7. Gleissner B, Siehl J, Korfel A, et al.: CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002, 58: 390–396.

    PubMed  CAS  Google Scholar 

  8. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J 2000, 1: 53–66.

    Article  PubMed  CAS  Google Scholar 

  9. Shenkier TN, Blay JY, O’Neill BP, et al.: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005, 23: 2233–2239.

    Article  PubMed  Google Scholar 

  10. Jahnke K, Thiel E, Schilling A, et al.: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol 2005, 128: 616–624.

    Article  PubMed  Google Scholar 

  11. Montesinos-Rongen M, Kuppers R, Schluter D, et al.: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999, 155: 2077–2086.

    PubMed  CAS  Google Scholar 

  12. Camilleri-Broet S, Criniere E, Broet P, et al.: A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006, 107: 190–196.

    Article  PubMed  CAS  Google Scholar 

  13. Braaten KM, Betensky RA, de Leval L, et al.: BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003, 9: 1063–1069.

    PubMed  CAS  Google Scholar 

  14. Montesinos-Rongen M, Van RoostD, Schaller C, et al.: Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004, 103: 1869–1875.

    Article  PubMed  CAS  Google Scholar 

  15. Nakamura M, Kishi M, Sakaki T, et al.: Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003, 63: 737–741.

    PubMed  CAS  Google Scholar 

  16. Weber T, Weber RG, Kaulich K, et al.: Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000, 10: 73–84.

    Article  PubMed  CAS  Google Scholar 

  17. Bellinzona M, Roser F, Ostertag H, et al.: Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005, 31: 100–105.

    Article  PubMed  CAS  Google Scholar 

  18. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23: 9–17. Only prospective (phase II) study on radiotherapy alone in PCNSL, resulting in a median survival of 12 months

    PubMed  CAS  Google Scholar 

  19. Shibamoto Y, Ogino H, Hasegawa M, et al.: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 2005, 62: 809–813.

    Article  PubMed  Google Scholar 

  20. Nelson DF: Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999, 43: 241–247.

    Article  PubMed  CAS  Google Scholar 

  21. Ferreri AJ, Reni M, Pasini F, et al.: A multicenter study of treatment of primary CNS lymphoma. Neurology 2002, 58: 1513–1520. Retrospective analysis of 370 patients treated for PCNSL with different regimens; high-dose methotrexate therapy improved survival in this cohort, but additional radiotherapy of the brain did not.

    PubMed  CAS  Google Scholar 

  22. Herrlinger U, Küker W, Uhl M, et al.: NOA-03 multicenter trial of high-dose methotrexate therapy in primary CNS lymphoma: final report. Ann Neurol 2005, 57: 843–847. Phase II study of high-dose methotrexate monotherapy, revealing a 29% complete response rate.

    Article  PubMed  CAS  Google Scholar 

  23. Batchelor T, Carson K, O’Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21: 1044–1049. Phase II study of high-dose methotrexate monotherapy, revealing a 52% complete response rate.

    Article  PubMed  CAS  Google Scholar 

  24. Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21: 2726–2731. Multicenter phase II study of methotrexate-based polychemotherapy without radiotherapy in older patients (median age 72 years), revealing a 48% complete response rate and a median survival of 14 months.

    Article  PubMed  CAS  Google Scholar 

  25. Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21: 4489–4495. First trial showing that sustained response can be achieved with polychemotherapy alone for PCNSL in patients aged younger than 61 years.

    Article  PubMed  CAS  Google Scholar 

  26. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. Clin Oncol 2000, 18: 3144–3150. Single-center phase II study of combination chemotherapy and radiotherapy revealing the best survival data (median overall survival = 60 months) and the highest rate (83%) of demented patients (aged > 60 years) after combination therapy.

    CAS  Google Scholar 

  27. DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20: 4643–4648. Multicenter phase II study of combination methotrexatebased chemo- and radiotherapy, revealing a median survival of 37 months.

    Article  PubMed  Google Scholar 

  28. Khan RB, Shi W, Thaler HT, et al.: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002, 58: 175–178.

    Article  PubMed  Google Scholar 

  29. Soussain C, Hoang-Xuan K, Levy V: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Bull Cancer 2004, 91: 189–192. Eight of 12 patients aged younger than 60 years refractory to or with a relapse after initial therapy achieved complete response with this salvage regimen.

    PubMed  Google Scholar 

  30. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21: 4151–4156.

    Article  PubMed  CAS  Google Scholar 

  31. Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31: 679–685.

    Article  PubMed  CAS  Google Scholar 

  32. Illerhaus G, Marks R, Derigs G, et al.: Primary CNS lymphoma: results of a multicenter phase II study including high-dose chemotherapy with autologous PBSCT and hyperfractionated radiotherapy as first-line-therapy. Ann Oncol 2005, 16(Suppl 5): v125.

    Google Scholar 

  33. Jahnke K, Korfel A, Martus P, et al.: High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005, 16: 445–449. Important interim analysis of an ongoing multicenter trial showing that high-dose systemic methotrexate is feasible in the older patient.

    Article  PubMed  CAS  Google Scholar 

  34. Blay JY, Conroy T, Chevreau C, et al.: High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998, 16: 864–871.

    PubMed  CAS  Google Scholar 

  35. O’Brien P, Roos D, Pratt G, et al.: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000, 18: 519–526. Multicenter phase II study of combination methotrexate and radiotherapy, revealing a median survival of 33 months

    PubMed  CAS  Google Scholar 

  36. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al.: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDSrelated primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21: 4483–4488. Multicenter phase II study of combination methotrexatebased chemo- and radiotherapy, revealing a median survival of 46 months in patients aged up to 65 years.

    Article  PubMed  CAS  Google Scholar 

  37. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16: 859–863. Important single-center analysis, which showed for the first time that nearly all older patients will suffer from late neurotoxicity after intensive combined chemo- and radiotherapy for PCNSL.

    PubMed  CAS  Google Scholar 

  38. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM: Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62: 451–456.

    PubMed  Google Scholar 

  39. Fliessbach K, Helmstaedter C, Urbach H, et al.: Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005, 64: 1184–1188. Neuropsychological evaluation of 23 long-term survivors after chemotherapy alone for PCNSL, showing no treatmentrelated cognitive dysfunction.

    PubMed  CAS  Google Scholar 

  40. Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62: 548–555. Neuropsychological evaluation of long-term survivors after therapy for PCNSL, showing more severe cognitive dysfunction after combination therapy than after chemotherapy alone.

    PubMed  CAS  Google Scholar 

  41. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005, 26: 258–265.

    PubMed  Google Scholar 

  42. Omuro AM, Ben-Porat LS, Panageas KS, et al.: Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005, 62: 1595–1600. Retrospective analysis of 183 patients treated for PCNSL revealed only the administration of radiotherapy as an independent risk factor for the development of neurotoxicity.

    Article  PubMed  Google Scholar 

  43. Harder H, Holtel H, Bromberg JE, et al.: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62: 544–547.

    PubMed  CAS  Google Scholar 

  44. Fisher B, Seiferheld W, Schultz C, et al.: Secondary analysis of Radiation Therapy Oncology Group (RTOG) study 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 2005, 74: 201–205.

    Article  PubMed  Google Scholar 

  45. O’Brien PC, Roos DE, Pratt G, et al.: Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 2006, 64: 408–413.

    Article  PubMed  Google Scholar 

  46. Herrlinger U, Küker W, Platten M, et al.: First-line therapy with temozolomide induces complete response in primary CNS lymphoma. Neurology 2002, 58: 1573–1574.

    PubMed  CAS  Google Scholar 

  47. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40: 1682–1688.

    Article  PubMed  CAS  Google Scholar 

  48. Antinori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDSrelated lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15: 1483–1491.

    Article  PubMed  CAS  Google Scholar 

  49. Hoffmann C, Tabrizian S, Wolf E, et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAARTinduced immune recovery. AIDS 2001, 15: 2119–2127. Multicenter retrospective analysis of PCNSL with AIDS. Median survival after cranial radiation and HAART was 1093 days, after cranial radiation alone was 132 days, and without specific therapy was 33 days.

    Article  PubMed  CAS  Google Scholar 

  50. Jahnke K, Korfel A, Komm J, et al.: Intraocular lymphoma 2000--2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 2006, In press.

  51. Smith JR, Rosenbaum JT, Wilson DJ, et al.: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002, 109: 1709–1716.

    Article  PubMed  Google Scholar 

  52. Reni M, Ferreri AJ: Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001, 80(Suppl 3): B113-B117. Salvage therapy of any kind improves survival, from 2 months without specific therapy to more than 1 year with treatment after relapse.

    PubMed  CAS  Google Scholar 

  53. Plotkin SR, Betensky RA, Hochberg FH, et al.: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004, 10: 5643–5646.

    Article  PubMed  CAS  Google Scholar 

  54. Reni M, Mason W, Zaja F, et al.: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004, 40: 1682–1688.

    Article  PubMed  CAS  Google Scholar 

  55. Enting RH, Demopoulos A, DeAngelis LM, et al.: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004, 63: 901–903.

    PubMed  CAS  Google Scholar 

  56. Fischer L, Thiel E, Klasen HA, et al.: Response of relapsed or refractory primary CNS lymphoma (PCNSL) to topotecan. Neurology 2004, 62: 1885–1887.

    PubMed  CAS  Google Scholar 

  57. Nguyen PL, Chakravarti A, Finkelstein DM, et al.: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005, 23: 1507–1513.

    Article  PubMed  Google Scholar 

  58. Küker W, Nägele T, Thiel E, et al.: Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 2005, 65: 1129–1131.

    Article  PubMed  Google Scholar 

  59. Palmedo H, Urbach H, Bender H, et al.: FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006, 33: 164–168.

    Article  PubMed  CAS  Google Scholar 

  60. Panageas KS, Elkin EB, DeAngelis LM, et al.: Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 2005, 104: 2466–2472. Progress in PCNSL therapy has not translated into clinical practice, as evidenced by this population-based analysis.

    Article  PubMed  Google Scholar 

  61. Wong ET: Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert Opin Pharmacother 2005, 6: 1107–1114.

    Article  PubMed  CAS  Google Scholar 

  62. Pels H, Schulz H, Schlegel U, Engert A: Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003, 26: 351–354.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Ruhr-University Bochum, Knappschaftskrankenhaus, In der Schornau 23-25, D-44892, Bochum, Germany

    Uwe Schlegel MD

Authors
  1. Hendrik Pels MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Schlegel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pels, H., Schlegel, U. Primary central nervous system lymphoma. Curr Treat Options Neurol 8, 346–357 (2006). https://doi.org/10.1007/s11940-006-0024-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-006-0024-8

Keywords

Search

Navigation